Neu-001 for Amblyopia Treatment Secures FDA Approval for Clinical Trials
Our first pipeline Neu-001,Neu-001, an innovative first-in-class small-molecule drug for treating amblyopia (commonly known as lazy eye), has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA). This milestone achievement was unveiled at a press…